Skip to content
Entourage
Article18 min read

Seven classifications codified, one exemption widened: what FDA’s final orders of September 30 to October 9, 2026 change

Between September 30 and October 9, 2026, FDA published eight final orders. Seven codify class II classifications from De Novo decisions of 2023 together with their special controls; the eighth widens 510(k) exemptions for 14 clinical toxicology test systems.

Diana Hohage

Diana Hohage

Principal Consultant

In brief

The orders open no new route to market: the classifications applied from the original De Novo orders, and for four of the seven device types 510(k) clearances already exist. What they add is a citable, binding description of the evidence FDA expects for each device type.

Status: November 3, 2026

Between September 30 and October 9, 2026, FDA published eight final orders on medical devices and in vitro diagnostics. Seven of them codify class II classifications with special controls for device types that FDA first classified in De Novo decisions issued between September and November 2023, and they write the special controls into the Code of Federal Regulations. The eighth widens existing 510(k) exemptions for 14 clinical toxicology test systems. The orders are in force. They are mainly a matter of legal text and predicate status: the classifications date from the original De Novo orders, which already identified the applicable special controls, and the 2026 orders codify both in the CFR. [1] [2] [3] [4] [5] [6] [7] [8]

That distinction matters for planning. A reader who takes “new classification” literally may assume that a market-access route opened in October 2026. For these seven device types it did not: the classification applied from the date of the De Novo order, and for four of the seven device types, namely the vascular autograft solution, focused ultrasound, the OTC infant monitor and the home-collected STI test, 510(k) clearances already exist. What the codification gives developers is a citable, binding description of the evidence FDA expects for each device type, and a clear signal about where the line runs between a classified device and one that would need a different pathway. [1] [10] [11]

Status of the orders

  • Final and in force: each order is effective on the date of its publication in the Federal Register (September 30, October 6 or October 9, 2026). [1] [2] [3] [4] [5] [6] [7] [8]
  • No open comment period: these are final orders; no comment deadline applies.

Key takeaways

  • Codification, not a new route. FDA states for all seven device types that the classification became applicable on the date of the original De Novo order in 2023. [1] [3] [4] [5] [6] [7] [8]
  • 510(k) remains required. FDA states that it has not exempted any of the seven device types under section 510(m) of the FD&C Act, and a device must comply with the special controls to stay out of automatic class III. [1] [3] [4] [5] [6] [7] [8]
  • The special controls are specific. The hereditary cancer panel order, for example, requires at least 120 variant-positive specimens for BRCA1 and BRCA2 and at least 40 per other gene of high clinical significance. [3]
  • Several orders evaluate a system, not just a product. The home-collection STI order covers the path from collection kit to reported result; the enrichment kit order requires the intended use to state that the end user is responsible for validating the device, and the labeling to describe any end-user validation needed for use with specific tests and collection devices. [7] [8]
  • The toxicology exemption removes a carve-out. Federal drug testing program devices are no longer excluded from existing 510(k) exemptions, but the employment-and-insurance labeling statement and the general limitations in 21 CFR 862.9 still apply. [2]

What a codifying final order does

When FDA grants a De Novo request, it classifies the device into class I or II by written order, and that De Novo classification is the device’s initial classification even though the device was automatically placed in class III beforehand. A device classified this way can serve as a predicate for a future device of that generic type. A sponsor may then use the 510(k) process instead of its own De Novo request or premarket approval application where the new device can be shown to be substantially equivalent to a legally marketed predicate; belonging to the same generic device type does not by itself open a 510(k) route. The orders discussed here follow with the codification step: they add a section to the CFR and write the special controls into it. [1]

Each of the seven orders states that the classification was applicable on the date of the De Novo order, and that the order itself is effective on publication. Each also states that FDA has not made a determination under section 510(m) to exempt the device type from 510(k), so premarket notification remains required. For a device to fall within the classification and avoid automatic class III, it has to comply with the special controls named in the order. [1] [3] [4] [5] [6] [7] [8]

Two clearances show that the route has been in use. FDA cleared DuraGraft Vascular Conduit Solution under K240925 on May 1, 2024, with the De Novo device as its predicate. A home-collection STI test, the Abbott simpli-COLLECT STI Test (K243410), was cleared on January 30, 2025, under the same classification regulation. [10] [11]

Device type21 CFRFR Doc.PublishedDe Novo device (applicant)Classified
Flushing and storage solution for vascular autografts at room temperature876.41002026-20075Sept 30DuraGraft Vascular Conduit Solution (Marizyme)Oct 4, 2023
High throughput DNA sequencing for hereditary cancer predisposition assessment866.60952026-20443Oct 6Invitae Common Hereditary Cancers Panel (Invitae)Sept 29, 2023
Hyperoxia monitoring device adjunct to pulse oximetry870.27202026-20441Oct 6ORi (Masimo)Oct 12, 2023
Focused ultrasound system for non-thermal, mechanical tissue ablation878.44052026-20440Oct 6Edison System (HistoSonics)Oct 6, 2023
Infant pulse rate and oxygen saturation monitor for over-the-counter use870.27052026-20726Oct 9Dream Sock (Owlet Baby Care)Nov 8, 2023
Nucleic acid detection system for non-viral sexually transmitted infections using home-collected specimens866.33852026-20727Oct 9Simple 2 Test (LetsGetChecked)Nov 15, 2023
Hematopoietic cell enrichment kit866.61202026-20725Oct 9EasySep Human Bone Marrow CD138 Positive Selection Kit (STEMCELL Technologies)Nov 6, 2023

Vascular autograft storage solutions (21 CFR 876.4100)

The regulation identifies the device type as a flushing and storage solution for vascular autografts at room temperature, used for flushing or short-term storage of vascular grafts and intended to maintain cell viability and structural integrity of grafts during short-term room-temperature storage during the surgical procedure. FDA published the order on September 30, 2026 (91 FR 61703; codified text at 61705). [1]

The special controls combine clinical, non-clinical and labeling elements. Clinical data must evaluate adverse events associated with clinical use, and devices indicated for vascular grafts in coronary artery bypass graft surgery must include the incidence of major adverse cardiac events, vein graft occlusion and mortality. Non-clinical testing must show maintenance of cell viability and structural integrity during storage at the labeled temperature and duration, and must evaluate visible and non-visible particulates in the final mixed solution. Shelf life testing must demonstrate chemical stability, and biocompatibility and sterility must be demonstrated. Labeling must state the maximum storage duration, any additives supplemented at the point of care, the need for visual inspection for particulate matter, the stability of the final solution after preparation, and summaries of the non-clinical and clinical data. [1]

FDA ties these controls to identified risks: adverse tissue reaction, damage to grafts leading to major adverse cardiac events or vascular injury, particulate contamination leading to occlusion, embolization, phlebitis, infarction or death, and infection. The device type is defined by its intended use: flushing or short-term storage of vascular grafts at room temperature during the surgical procedure. In our reading, which the order itself does not state, products intended for other uses do not fall within this device type merely because they are described as rinsing or storage solutions, and a product described only generically is not outside it if its actual intended use and labeling cover the use defined in 21 CFR 876.4100. The requirement to evaluate major adverse cardiac events, vein graft occlusion and mortality is written for devices indicated for vascular grafts in CABG surgery. [1]

Hereditary cancer predisposition panels (21 CFR 866.6095)

The classified device type is a qualitative in vitro diagnostic system for analysis of human DNA extracted from human specimens to detect germline mutations in a panel of targeted cancer-related genes. It is intended to aid hereditary cancer predisposition assessment by qualified health care professionals in accordance with professional guidelines, is for prescription use only, and is not intended for screening, prenatal testing or as a stand-alone diagnostic test. [3]

The special controls are among the most detailed of the group. Design verification and validation must document genomic coverage (genes, variant types, target regions and regions that cannot be reported), specimen and DNA requirements, methodology including analysis algorithms, quality metrics, variant calling thresholds and filters, criteria for run, batch and specimen failures, invalid calls and no-calls, software verification, validation and hazard analysis, controls, and the probability of test failure. The rules, databases and procedures used for variant annotation and classification must be documented, including protocols for variant interpretation, monitoring accuracy, resolving discordant interpretations and updating interpretations, and the clinical significance of each gene on the panel must be summarized. [3]

The analytical requirements contain numbers. Accuracy is evaluated against bidirectional Sanger sequencing or other orthogonal methods that FDA finds appropriate, with predefined criteria. For BRCA1 and BRCA2, a minimum of 120 variant-positive specimens must be tested; for other genes of high clinical significance, at least 40 variant-positive specimens per gene, including representative specimens for each indicated variant type on a justification that FDA finds appropriate and acceptable. For remaining genes, testing must include variant-positive specimens representing each variant type, unless the prevalence of that variant type is below 0.01 percent. Positive and negative percent agreement must be calculated per variant type with 95% two-sided confidence intervals. Overall accuracy for reporting must be at least 99.0 percent for substitutions and for insertions and deletions, and for copy number variants at least 99.0 percent for positive agreement (PPA, TPPV). The same sentence of the regulation adds at least 99.9 percent for negative agreement (NPA, TNPV); its wording does not make clear whether that threshold applies only to copy number variants or to all variant types. Precision studies must use multiple instruments, operators, non-consecutive days and reagent lots, with overall precision point estimates above 99.0 percent for each variant type. Labeling must include specified limiting statements, for example that the test is not a stand-alone diagnostic or cancer screening test, that it is designed for heritable germline mutations and that a negative result does not rule out an unidentified variant. [3]

Hyperoxia monitoring adjunct to pulse oximetry (21 CFR 870.2720)

The device monitors elevated hemoglobin oxygen saturation as an adjunct to arterial oxygen saturation monitoring. Clinical performance testing under anticipated conditions of use must evaluate the accuracy of hyperoxia monitoring and all adverse events. Human factors testing must demonstrate that users can correctly use the device based solely on reading the instructions for use. Further controls cover electromagnetic compatibility, electrical safety, biocompatibility of patient-contacting components, validation of reprocessing instructions including performance after repeated cleaning and disinfection, and software verification, validation and hazard analysis, including compatibility with pulse oximeters labeled to be compatible. Labeling must include cleaning and disinfection instructions, a summary of the clinical performance testing, a warning against over-reliance on device output without arterial blood gas confirmation, and instructions to monitor oxygen delivery and the patient’s clinical and cardiovascular status when the output changes. [4]

Focused ultrasound for non-thermal, mechanical tissue ablation (21 CFR 878.4405)

The device uses focused ultrasound to mechanically ablate soft tissue and is not intended to thermally ablate tissue. The special controls require clinical performance testing that documents the adverse event profile and characterizes tissue destruction, and animal performance testing that demonstrates mechanical destruction of targeted tissue while characterizing the chronic safety profile, including thermal and mechanical injury to adjacent non-target tissue. Non-clinical testing must cover acoustic characterization at clinically relevant settings, the minimum drive voltages needed to sustain a bubble cloud, mechanisms that prevent energy delivery causing adverse thermal effects, real-time monitoring during the procedure, limitation of the treatment zone to the defined target tissue, and mechanisms to prevent, pause and terminate ablation on device failure. Electrical safety and electromagnetic compatibility, biocompatibility, software validation and human factors testing are also required. [5]

Labeling must include a warning that ablation should only be considered in patients with sufficient functional reserve to withstand destruction of the planned tissue volume, a statement that the device has not been evaluated for the treatment of any specific disease or condition, and a detailed summary of the clinical testing. This statement should not be read in isolation as a blanket prohibition on disease-specific indications: the De Novo grant for the Edison System, which carries the same labeling statement, covers the non-invasive destruction of liver tumors, including unresectable liver tumors, while FDA’s decision summary for that grant adds that the safety and effectiveness of the device for the treatment of cancer has not been established. In our reading, the indication therefore concerns tissue destruction in a defined organ context, not the treatment of a disease. Any additional or different indication would need to be assessed against the applicable submission requirements and supporting evidence. [5] [12]

OTC infant pulse rate and oxygen saturation monitors (21 CFR 870.2705)

The device type uses photoplethysmography to measure pulse rate and oxygen saturation in infants and may contain alarms that alert the caregiver when vital signs go outside preset thresholds. The identification is functional: it describes what the device measures and in whom. [6]

Clinical performance testing must evaluate the effect of confounding variables such as skin pigmentation, demonstrate consistency of output and representativeness of data sources and data quality in the intended use population and environment, and evaluate all adverse events including skin irritation. Software documentation must include algorithm specifications and acceptable incoming sensor data quality control measures. Non-clinical testing must show that the device detects adequate signal quality and validate any alarms. Skin-contacting components must be biocompatible, and electrical safety and electromagnetic compatibility must be supported. Human factors testing must show that the caregiver can correctly use the device based solely on its labeling and can correctly interpret outputs and understand next steps. Labeling must address the intended population including where the device should not be used, what the device measures and how to interpret outputs, situations in which performance may fall short, and cleaning. FDA names misinterpretation and overreliance on output, leading to failure to seek treatment despite acute symptoms, among the identified risks. [6]

STI nucleic acid tests with home-collected specimens (21 CFR 866.3385)

The device type is an in vitro diagnostic system for self-collection of specimens in home settings or similar environments, with testing in a clinical laboratory, for detection of nucleic acids from non-viral microorganisms causing sexually transmitted infections. It is intended to aid in the diagnosis of those infections, and it can be for prescription or over-the-counter use. [7]

The special controls treat collection, shipment and result as one system. The sample collection device must be FDA-cleared, -approved or 510(k)-exempt with an over-the-counter in vitro diagnostic indication for molecular testing, or be cleared as part of the device with performance data showing that lay users can correctly collect specimens without health care provider supervision. Indications are limited to specimens appropriate for lay collection with such data. Design verification and validation must describe the process from acquisition of the collection kit to results reporting and include a clinical study with prospective self-collected samples for each claimed specimen type in a population consistent with the intended use population. Risk analysis must rely, as applicable, on usability, user label comprehension and flex studies. Analytical studies cover limit of detection, inclusivity, cross-reactivity, microbial interference, interfering substances, competitive inhibition, carryover and cross-contamination, specimen stability, within-lab precision and reproducibility; specimen integrity during handling and shipping must be validated. [7]

Labeling requirements go further than for many laboratory tests: instructions for collection and shipping written for the intended user, a frequently asked questions section, specified warnings (for example that a negative result does not preclude infection with other pathogens and that the system is not a substitute for a health care provider), accessioning criteria for the laboratory, outer box information, and a prominent hyperlink to a public website. That website must make key information available, including the required warnings, the performance characteristics and, for tests intended to detect antimicrobial resistance markers, specified limiting statements, for example that negative results for claimed markers do not indicate susceptibility. [7]

Hematopoietic cell enrichment kits (21 CFR 866.6120)

The device is an immunomagnetic bead-based kit for selecting and enriching specific hematopoietic cells from whole blood or bone marrow of patients with hematological malignancies, intended for use with diagnostic assays as part of the pre-analytical workflow. [8]

Special controls require that any sample collection device be cleared, approved or 510(k)-exempt for the relevant sample types, or cleared as part of the kit. The intended use must name the specimen type for each malignancy for which acceptable enrichment has been demonstrated, using the minimum volume that ensures a 95 percent accurate call rate at the limit of detection, describe the enrichment targets and state that the end user is responsible for validating the device with the assay. Studies for each specimen type and malignancy combination cover recovery, limit of detection against a flow cytometry reference method, reproducibility, specificity including interference, and sample stability. The reproducibility study must include multiple operators, multiple runs, different instruments and three reagent lots, specimens with low, medium and high starting target levels, and specimens with different genetic alterations representative of the indication. Reagent stability and shipping stability must be demonstrated separately. Labeling must state, among other things, that bone marrow stability is severely compromised after 48 hours unless data support another period, that the device is only for enriching specimens for further analysis by independent methods, that results do not provide information about health conditions and that it is not intended for cell enumeration. [8]

Clinical toxicology test systems: a carve-out removed

The eighth order does not classify anything. It amends 14 existing class II classification regulations in 21 CFR Part 862 (amphetamine, barbiturate, benzodiazepine, cocaine and cocaine metabolite, codeine, LSD, methamphetamine, methadone, methaqualone, morphine, opiate, propoxyphene, cannabinoid and tricyclic antidepressant test systems) and took effect on publication on October 6, 2026 (91 FR 63478). [2] [9]

Before the order, these regulations exempted from 510(k) test systems intended for employment and insurance testing and labeled as intended solely for that use, but excluded devices intended for Federal drug testing programs. FDA removed that exclusion; examples of such programs are those run by the Substance Abuse and Mental Health Services Administration, the Department of Transportation and the U.S. military. The exemption still depends on the employment-and-insurance intended use and labeling statement and on the general limitations of 21 CFR 862.9, so a device with a different intended use or a different fundamental scientific technology than a legally marketed device of that generic type is not exempt. FDA says that fentanyl test systems generally fall under the opiate test system regulation. FDA announced its intent on May 1, 2026, received comments from about 70 commenters and finalized the exemptions without modification. [2]

The order also draws boundaries. It does not exempt oral fluid collection devices or phencyclidine test systems, does not replace the 510(k) requirement with other standards, and does not decide whether oral fluid or hair testing may be used in Federal programs, because FDA does not oversee those programs. Manufacturers remain subject to applicable FDA requirements, including establishment registration, device listing, quality management system, labeling and medical device reporting requirements. FDA also states that exempt devices remain subject to other applicable requirements, including SAMHSA’s mandatory guidelines to the extent they are used in Federal drug testing programs, and it describes those guidelines as requirements overseen by SAMHSA for the programs and for the laboratories that test samples under them. FDA declined to adopt a general enforcement discretion policy for labeling of previously exempt devices, and it points manufacturers with questions about the scope of the exemption to a section 513(g) request for information. [2]

What this means for planning

Treat the codified text as a checklist, and the intended use as the starting point. Each identification defines the device type by function and intended use. Intended use and indications for use, together with the labeling, should be mapped against the identification before the evidence plan is built, because a product outside the identification is not covered by the classification or its special controls. [1] [3] [4] [5] [6] [7] [8]

Plan for system evidence where the order asks for it. For home-collected STI tests, the clinical study, lay-user collection data, usability studies and shipping validation are part of the premarket evidence. For enrichment kits, the intended use must state that the end user is responsible for validation of the device. For infant monitors, human factors work addresses interpretation by the caregiver, not only correct application. [6] [7] [8]

Use the numbers. For hereditary cancer panels, specimen numbers, accuracy thresholds and precision requirements are explicit; changes to the gene panel, variant types, pipeline or annotation databases need to be checked against them. For autograft solutions and focused ultrasound systems, specific clinical and animal performance requirements apply. [3] [1] [5]

Read exemptions narrowly. For toxicology test systems, check intended use, labeling statement, analyte, technology and product code against the order and 21 CFR 862.9 for each product, and consider a section 513(g) request when the boundary is unclear. [2]

For EU portfolios, this is our assessment, not a legal consequence of the U.S. orders: we regard these orders as external technical context for performance evaluation, usability and risk management, not as a source of EU obligations. Nothing in them changes the classification or conformity assessment of a device under the EU Medical Device Regulation or the In Vitro Diagnostic Regulation; any use of the U.S. requirements as state-of-the-art information is a judgment to be documented in the manufacturer’s own risk management and clinical or performance evaluation.

Image notice: The illustrative and header images were generated using AI and do not depict real people, places, or events. The portrait photographs show real people.

Relevant for your project?

Similar questions in your current project?

In a first call we clarify what is specifically relevant for your situation, without obligation.

Request a call →

Regulations & standards considered

  • FDA final orders codifying seven De Novo classifications with special controls: 21 CFR 876.4100, 866.6095, 870.2720, 878.4405, 870.2705, 866.3385 and 866.6120
  • FDA final order on 510(k) exemptions for certain clinical toxicology test systems, 21 CFR Part 862 (91 FR 63478) and the general limitations in 21 CFR 862.9
  • Section 510(m) of the FD&C Act (exemption from premarket notification) and section 513(g) (request for information)

FAQ

Frequently asked questions

No. FDA states for all seven device types that the classification applied from the date of the original De Novo order in 2023. For four of the seven device types, 510(k) clearances already exist, for example K240925 for DuraGraft Vascular Conduit Solution and K243410 for the Abbott simpli-COLLECT STI Test. What the orders add is the identification and the special controls written into the Code of Federal Regulations.

Sources

De Novo and 510(k)

Does your device fall within one of the codified classifications?

The intended use, the indications and the planned submission are all we need at first.

Your inquiry goes to our team, which brings in the subject-matter experts as needed.

Prefer direct? +39 02 8904 1000
contact@theentourage.it

  • Reply usually within one working day
  • 3 locations: DE · CH · IT · projects in the US too
  • 100% life sciences